Peficitinib

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

353 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Peficitinib.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Peficitinib.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peficitinib.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peficitinib.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Peficitinib.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Peficitinib.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Peficitinib.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Peficitinib.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Peficitinib.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Peficitinib.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Peficitinib.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peficitinib.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peficitinib.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Peficitinib.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peficitinib.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peficitinib.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Peficitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Peficitinib.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Peficitinib.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peficitinib.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Peficitinib.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peficitinib.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Peficitinib.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Peficitinib.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peficitinib.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peficitinib.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Peficitinib.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Peficitinib.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Peficitinib.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Peficitinib.
Cladribine	Peficitinib may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Peficitinib.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Peficitinib.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Peficitinib.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Peficitinib.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Peficitinib.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Peficitinib.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Peficitinib.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Peficitinib.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Peficitinib.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Peficitinib.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Peficitinib.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Peficitinib.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Peficitinib.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Peficitinib.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Peficitinib.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Peficitinib.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Peficitinib.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Peficitinib.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Peficitinib.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Peficitinib.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Peficitinib.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Peficitinib.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Peficitinib.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Peficitinib.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Peficitinib.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Peficitinib.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Peficitinib.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Peficitinib.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Peficitinib.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Peficitinib.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Peficitinib.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Peficitinib.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Peficitinib.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Peficitinib.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Peficitinib.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Peficitinib.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Peficitinib.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Peficitinib.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Peficitinib.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Peficitinib.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Peficitinib.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Peficitinib.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Peficitinib.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Peficitinib.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Peficitinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Peficitinib.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Peficitinib.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Peficitinib.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Peficitinib.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Peficitinib.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Peficitinib.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Peficitinib.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Peficitinib.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Peficitinib.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Peficitinib.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Peficitinib.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Peficitinib.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Peficitinib.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Peficitinib.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Peficitinib.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Peficitinib.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Peficitinib.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Peficitinib.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Peficitinib.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Peficitinib.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Peficitinib.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Peficitinib.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Peficitinib.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Peficitinib.

Target Protein

Tyrosine-protein kinase JAK3 JAK3

Tyrosine-protein kinase JAK1 JAK1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual